Brief: Tiziana Life Sciences To Focus On Intranasal Foralumab Central Nervous System Diseases

Tiziana Life Sciences

10/11/2022 13:32

Nov 10 (Reuters) - Tiziana Life Sciences Ltd  TLSA.O :
    * TIZIANA LIFE SCIENCES ANNOUNCES NEAR-TERM STRATEGIC FOCUS
ON
INTRANASAL FORALUMAB FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM
(CNS)
    * TIZIANA LIFE SCIENCES LTD - EXPECTS TO ANNOUNCE RESULT OF
SIX-MONTH PET SCAN ON PATIENT EA2 AND NINE-MONTH PET SCAN ON
PATIENT EA1 ALSO IN Q1 OF 2023
    * TIZIANA LIFE SCIENCES LTD - DURING Q1 OF 2023, COMPANY
THEN
PLANS TO PERFORM THREE-MONTH PET SCANS ON PATIENTS EA3 THROUGH
EA6
    * TIZIANA LIFE SCIENCES LTD -  ANTICIPATING RESULTS FROM
THREE-MONTH PET SCANS ON PATIENTS EA3 THROUGH EA6 TO BE
AVAILABLE IN Q2 2023
    * TIZIANA LIFE SCIENCES - IN Q4, EXPECT TO REQUEST A TYPE C
MEETING WITH FDA TO DISCUSS PHASE 2 PROGRAM FOR EVALUATING
FORALUMAB IN NON-ACTIVE SPMS PATIENTS
    * TIZIANA LIFE SCIENCES -  EXPECT TO RECEIVE FEEDBACK FROM
FDA ON
PHASE 2 PROGRAM FOR EVALUATING FORALUMAB IN NON-ACTIVE SPMS
PATIENTS BY Q1 2023 END

Source text for Eikon:  ID:nGNX1228b7 
Further company coverage:  TLSA.O 
 ((Reuters.Briefs@thomsonreuters.com;))